Will there be drug resistance after taking apalutamide (Ansenko) and its treatment plan?

Apalutamide (Apalutamide) is a non-steroidal androgen receptor inhibitor, mainly used to treat castration-resistant prostate cancer (CRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC). During clinical use, patients taking apalutamide for a long time may develop drug resistance. This is mainly due to the mutation of the androgen receptor (AR) signaling pathway of tumor cells or the activation of the bypass signaling pathway, which weakens the inhibitory effect of drugs on cancer cells, causing serum PSA levels to rise again, or the lesions to continue to progress. The time to occurrence of drug resistance varies between individuals, generally ranging from months to years of use.

For the treatment of apalutamide resistance, it is first clinically recommended to regularly monitor serumPSA and imaging examinations to detect disease progression in a timely manner. For patients who develop drug resistance, replacement or combination with other treatment strategies may be considered. For example, other new AR inhibitors or multi-targeted treatment options can be considered based on the patient's genetic mutation; some patients with obvious progression can also be switched to chemotherapy or targeted therapy. Such protocols should be formulated under the guidance of professional urological oncologists to ensure maximum efficacy and controllable side effects.

In the process of dealing with drug resistance, the clinic will also adjust individualized plans based on the patient's overall health status and previous medication history. Some patients can use apalutamide in combination with other drugs, such as ADT (androgen deprivation therapy) or other new endocrine therapy drugs, to delay the development of drug resistance. Studies have shown that combination therapy can prolong progression-free survival (PFS) and reduce the risk of disease progression to a certain extent, but hematological and cardiovascular adverse reactions need to be closely monitored.

Generally speaking, apalutamide resistance is a common problem in clinical treatment, but through early monitoring, individualized medication adjustment and reasonable combination treatment, the progression of the disease can still be effectively delayed. Patients should strictly follow the doctor's instructions during use and are not allowed to increase or decrease the dosage or stop medication on their own. At the same time, regular review and psychological support are also important measures to improve treatment compliance and extend the duration of therapeutic effect.

Reference materials:https://www.drugs.com/